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Abstract
Background: Intrathecal baclofen pump has been used effectively with increasing frequency in
patients with severe spasticity, particularly for those patients who are unresponsive to conservative
pharmacotherapy or develop intolerable side effects at therapeutic doses of oral baclofen.
Drowsiness, nausea, headache, muscle weakness, light-headedness and return of pretreatment
spasticity can be caused by intrathecal pump delivering an incorrect dose of baclofen. Intrathecal
baclofen withdrawal syndrome is a very rare, potentially life-threatening complication of baclofen
pump caused by an abrupt cessation of intrathecal baclofen.
Case presentation: A 24-year-old man with a past medical history of cerebral palsy and spastic
quadriparesis developed hyperthermia, disseminated intravascular coagulation, rhabdomyolysis,
acute renal failure and multisystem organ failure leading to a full-blown intrathecal baclofen
withdrawal syndrome. Intrathecal baclofen pump analysis revealed that it was stopped due to some
programming error. He was treated effectively with supportive care, high-dose benzodiazepines
and reinstitution of baclofen pump.
Conclusion: The episodes of intrathecal baclofen withdrawal syndrome are mostly caused by
preventable human errors or pump malfunction. Educating patients and their caregivers about the
syndrome, and regular check-up of baclofen pump may decrease the incidence of intrathecal
baclofen withdrawal syndrome. Oral baclofen replacement may not be an effective method to treat
or prevent intrathecal baclofen withdrawal syndrome. Management includes an early recognition
of syndrome, proper intensive care management, high-dose benzodiazepines and prompt analysis
of intrathecal pump with reinstitution of baclofen.
Background
Baclofen is a gamma-aminobutyric acid (GABA) analog
that has inhibitory effects on spinal cord reflexes and
brain. Intrathecal baclofen (ITB) therapy consists of long-
term delivery of baclofen to the intrathecal space. Intrath-
ecal baclofen has been used to treat spasticity due to cere-
bral palsy, brain or spinal cord injury, multiple sclerosis,
dystonia, stroke and stiff-man syndrome, particularly for
those patients who are unresponsive to conservative phar-
macotherapy or develop intolerable side effects at thera-
peutic doses of oral baclofen [1]. Side effects such as
drowsiness, nausea, headache, muscle weakness and
light-headedness can occur as a result of the pump deliv-
ering an incorrect dose of baclofen. Sudden cessation of
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ITB administration can cause mild symptoms like reap-
pearance of baseline level of spasticity associated with
pruritis, anxiety and disorientation [2]. These mild symp-
toms represent "loss of drug effect". All patients experi-
ence "loss of drug effect" when ITB is discontinued, only
a small (but unknown) proportion of patients develop a
full-blown potentially life-threatening withdrawal syn-
drome. We report a case of ITB withdrawal syndrome
developing hyperthermia, severe spasticity, disseminated
intravascular coagulation, rhabdomyolysis, acute renal
failure and multisystem organ failure.
Case presentation
A 24-year-old man was admitted to our intensive care unit
(ICU) with a possible diagnosis of seizure disorder and
sepsis. He had a past medical history of cerebral palsy and
spastic quadriparesis. Three years ago, he had an ITB
pump implanted for spasticity refractory to the high doses
of oral baclofen. He had a significant improvement in
spasticity, social and functional capacity in the past three
years.
Later, he developed some disorientation and increased
spasticity. He was taken to a local physician who pre-
scribed oral baclofen (120 mg daily in four divided doses)
for his increased spasticity. He also advised him to have
his ITB pump checked immediately. The following day,
his spasticity increased even after taking oral baclofen. He
developed multiple seizures and respiratory distress in the
next 24-hour period. Subsequently, he was admitted in a
local hospital where he was orally intubated and trans-
ferred to our ICU for aggressive management.
On presentation, his temperature was 104.6°F (40.3°C),
heart rate 127 beats per minute, and the blood pressure
was 85/45 mm/Hg. His ventilator settings were: assist-
control ventilation mode; respiratory rate, 15 breaths per
minute; tidal volume, 650 mL; positive end expiratory
pressure (PEEP), 5 cm H2O; and FiO2, 60%. His sponta-
neous respiratory rate was 18 breaths per minute and an
oxygen saturation of 100% was noted on pulse oximetry.
In the local hospital, he was documented to have a high
fever of 107°F (41.6°C) and he had received intravenous
lorazepam, phenytoin, pantoprazole, piperacillin/tazo-
bactem and dopamine. On physical examination, neuro-
logically he was unconscious with decerebrate posturing
and his Glasgow coma scale was 6. He had an absent cor-
neal and gag reflexes. He was moving all four limbs in
response to noxious stimuli. He was also noted to have an
extreme spasticity in all four limbs. Lung examination
revealed decreased breath sounds in the left lower base.
Cardiac examination was unremarkable. He had a palpa-
ble baclofen pump on abdominal wall and bowel sounds
were heard. The differential diagnoses were septic shock,
meningitis, neuroleptic malignant syndrome and malig-
nant hyperthermia.
The initial laboratory results showed serum creatinine
phosphokinase (CPK) 5250 U/L (Normal, 25–235 U/L)
and CPK-MB fraction 12.1 ng/ml (Normal, 0.5–6.3 U/L).
Serum chemistry revealed sodium 142 mmol/L, potas-
sium 5.1 mmol/L, chloride 120 mmol/L, bicarbonate 13
mmol/L, and creatinine 2.1 mg/dl. Hemogram showed
white blood cell count 12.2 K/UL, hemoglobin 16.5 g/dl
and platelet count 9 K/UL (Normal, 130–400 K/UL). Liver
function test showed aspartate aminotransferase (ALT)
1128 U/L, alanine aminotransferase (AST) 1140 U/L,
alkaline phophatase 90 U/L, total bilirubin 1.2 mg/dl,
conjugated bilirubin 0.7 mg/dl, prothrombin time 20.2
seconds (Normal, 10–12.5 seconds), and INR 2.0 (Nor-
mal, 0.9–1.1). Blood and urine cultures were obtained.
Chest radiograph was normal. A computed tomography
(CT) scan of the chest revealed atelectasis of the left lung
base. His CT scan of head did not show any acute infarct
or bleeding. His initial management included intravenous
fluids, norepinephrine, platelet transfusion, phenytoin,
propofol and broad-spectrum antibiotics (vancomycin,
ceftriaxone) for suspected meningitis and septic shock. He
received intravenous lorazepam (4–8 mg every four
hours) for his spasticity. Next day, his spasticity improved
and an ITB specialist investigated his baclofen pump. His
baclofen pump analysis revealed that it was stopped due
to some programming error, which was restarted at a pre-
viously prescribed baclofen rate (260 µg/day).
On third hospital day, his serum CPK was 15,878 U/L,
AST was 2566 U/L, ALT was 2993 U/L, while CPK-MB frac-
tion came down to 3.4 ng/ml. His urine output decreased
(<400 ml/ day) and serum creatinine increased in the
range of 5–6 mg/dl. Later, he was hemodialyzed few times
during the course of hospitalization due to acute renal
failure. His echocardiogram showed left ventricular ejec-
tion fraction of 20–25% and severe global hypokinesis.
His electroencephalogram did not reveal any epilep-
togenic activity. He developed full-blown multisystem
organ failure with an evidence of shock liver, renal failure,
respiratory failure, disseminated intravascular coagula-
tion and myocardial depression. His nutrition was started
on nasogastric tube feedings, and proper ventilator care
was taken through a tracheostomy tube. His serum
baclofen obtained at the time of admission was less than
0.02  µg/ml (Expected values, 0.08–0.4 µg/ml). After a
three-week course of aggressive management in ICU, he
was weaned off from the ventilator and his multiple organ
shock resolved. At a six-month follow-up, he was
observed in a nursing home with his baseline functional,
social, and family activities.BMC Clinical Pharmacology 2004, 4:6 http://www.biomedcentral.com/1472-6904/4/6
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Discussion
Intrathecal baclofen provides an effective improvement in
the spasticity of patients whose spasticity is not suffi-
ciently managed by oral baclofen or other oral anti-spastic
medications [1]. Regardless of the cause of spasticity (cer-
ebral or spinal), anti-spastic effects of baclofen occur at
spinal level. Poor response of oral baclofen in many
patients can be explained by the fact that the spinal cord
represents only about 2% mass of the brain, and receives
proportionately a lower blood flow as a fraction of cardiac
output. Therefore, cerebral side effects often occur before
therapeutic anti-spastic effects of oral baclofen are
observed. A programmable ITB pump provides a direct,
pattern-controlled delivery of baclofen to the spinal cord.
Precise delivery of the ITB pump yields better spasticity
reduction at 1000 times lower than the doses of oral
baclofen. In addition, the adverse effects are minimized as
compared with oral baclofen. ITB provides reduced tone,
spasms and pain, improves speech, mobility, sleep quality
and bladder control, with a response rate up to 97% in
adults and children [3,4]. The ITB pump is approximately
3 inches wide and 1 inch thick. It is surgically implanted
in the subcutaneous tissue of anterior abdominal wall.
Baclofen is delivered via a silicone rubber catheter into the
lumbar subarachanoid space. The ITB pump delivers
approximately 100–900 µg/day of baclofen, and it is
titrated for the desired clinical response. It is also
equipped with an alarm that signals low volume, low bat-
tery, or malfunction. Nine years ago, catheter or pump-
related malfunction that leads to an overdose or with-
drawal has been reported in 40 % of the patients with ITB
pump [5]. Catheter system, operative techniques and pro-
gramming system of the ITB pump have now been
improved significantly to reduce the incidence of an over-
dose or withdrawal.
The precise mechanism of action of baclofen as a muscle
relaxant and anti-spasticity agent is not fully understood.
Baclofen inhibits both monosynaptic and polysynaptic
reflexes at the spinal cord level [6], possibly by decreasing
excitatory neurotransmitter release from primary afferent
terminals, although actions at supraspinal sites may also
contribute to its clinical effects. Baclofen also causes
enhancement of vagal tone and inhibition of mesolimbic
and nigrostriatal dopamine neurons (directly or via inhib-
iting substance P) [7]. Baclofen is a structural analog of
the inhibitory neurotransmitter GABA, and may exert its
effects by stimulation of the GABAB receptor to cause mus-
cle relaxation. Baclofen reduces increased muscle tone,
Babinski sign, tendon reflexes, ankle clonus and some-
times decreases muscle force.
Long-term ITB infusion causes down-regulation of GABAB
receptors in the CNS and spinal cord. Down-regulation of
GABAB receptors accounts for the decreased sensitivity to
the baclofen over time. Although GABAB receptors are
down-regulated, it is the baclofen itself that causes
increased inhibitory tone in the CNS and spinal cord [8].
Therefore, abrupt ITB withdrawal results in a predomi-
nance of excitatory effects and simulates other conditions
that are associated with CNS hyperexcitability and severe
spasticity. Sudden cessation of ITB administration can
cause mild symptoms like reappearance of baseline level
of spasticity associated with pruritis, anxiety and disorien-
tation. These mild symptoms represent "loss of drug
effect". All patients experience "loss of drug effect" when
ITB is discontinued. However, more severe symptoms like
hyperthermia (109.4°F), myoclonus, seizures [9-12],
rhabdomyolysis, disseminated intravascular coagulation,
multisystem organ failure [10], cardiac arrest, coma and
death [9,12,13] have been well reported, and represents a
full-blown life-threatening ITB withdrawal syndrome.
Food and drug administration (FDA) of USA has included
a drug label warning for baclofen withdrawal syndrome in
April 2002 [1,13]. Differential diagnoses include malig-
nant hyperthermia, neuroleptic-malignant syndrome,
autonomic dysreflexia, sepsis and meningitis. ITB with-
drawal syndrome has been fatal in some cases. Six patients
have died out of 27 cases reported to FDA [13]. Most
reported episodes of ITB withdrawal were caused by pre-
ventable human errors or oversights. However, catheter
dislodgement, catheter migration and kinks, and other
catheter-related issues might be more common than
pump-related malfunctions [1,14]. Close attention to
pump refilling and programming procedures may reduce
the incidence of ITB withdrawal syndrome.
Benzodiazepines are helpful in controlling spasticity and
seizures during ITB withdrawal syndrome [1,10]. Benzo-
diazepines activate central receptors and GABAA receptors
of spinal cord by different mechanisms [1]. Therefore, ITB
induced down-regulation of GABAB  receptors do not
interfere with benzodiazepine's mechanism of action.
During a planned removal of ITB pump due to infection
or other causes, premedication with high doses of benzo-
diazepines and augmented oral baclofen is usually
administered in the hospitals to prevent spasticity. Simi-
larly, high doses of oral baclofen is also tried in some cases
of ITB withdrawal syndrome [15,16]. But failure of high
doses of oral baclofen (80 mg three times daily) have been
reported recently [17]. High doses of oral baclofen may
not be adequate to treat or prevent ITB withdrawal
because of down-regulation of central GABAB receptors
due to chronic ITB administration. Moreover, it has been
suggested that it may take many hundreds of grams of oral
baclofen to achieve a therapeutic baclofen level in the cer-
ebrospinal fluid, compared to the patients who had effec-
tive spasticity control with an ITB pump [17]. Although,
our patient received oral baclofen (120 mg daily in four
divided doses) initially but these doses may be lowBMC Clinical Pharmacology 2004, 4:6 http://www.biomedcentral.com/1472-6904/4/6
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enough to prevent ITB withdrawal syndrome. Failure of
high doses of oral baclofen suggests that resumption of
GABAB receptor agonist by prompt restoration of ITB
pump and proper supportive care might be the best treat-
ment. Similarly, high-dose benzodiazepines may be effec-
tive because of similar mechanism of action on
widespread CNS GABAA receptors. High-dose benzodi-
azepines could be an initial life saving strategy even before
analysis and restoration of ITB pump is achieved, or in
cases, where resumption of ITB administration is not as
simple as correcting a programming error.
Intrathecal baclofen bolus is appropriate, but due to the
risk of inadvertent overdose, an experienced physician
should immediately perform reinstitution of ITB pump.
We had restarted ITB in our patient at a previously pre-
scribed dose. However, a much higher dose of baclofen
could have safely been given to overcome the spasticity
since the patient was in an ICU. High-dose dantrolene (a
direct muscle relaxant that acts on sarcoplasmic reticulum
of skeletal muscle) has been tried to reduce spasticity and
fever in ITB withdrawal syndrome [18]. Reduction in fever
may be due to cessation of repetitive and thermogenic
contractions of muscle fibers. It is unlikely that dantrolene
has any GABA agonistic effects, and administration of
dantrolene may not be accompanied by any correction in
anomalies of CNS functions. Therefore, seizures, auto-
nomic instability and death may occur in ITB withdrawal
syndrome even after controlling spasticity with dantro-
lene. Cyproheptadine (a non-selective serotonin antago-
nist) has also been used postulating that ITB withdrawal
may be a form of serotonergic syndrome that occurs from
the loss of GABAB receptor-mediated presynaptic inhibi-
tion of serotonin [19]. We did not consider dantrolene or
cyproheptadine in our patient due to lack of sufficient
clinical support in the treatment of ITB withdrawal syn-
drome. There was a three-day period of delay in diagnos-
ing the ITB withdrawal syndrome leading to deterioration
and multisystem organ failure. However, our patient had
a successful recovery in response to restoration of
baclofen pump and adequate intensive care management.
Conclusions
Baclofen withdrawal syndrome is a potentially life-threat-
ening complication of intrathecal baclofen pump. Empty
pump reservoir, catheter leaks or displacement, pump
malfunction, programming error and refill of pump with
improper drug concentration are the possible mecha-
nisms which could lead to an ITB withdrawal syndrome.
Regular check-up of the ITB pump by a specialist, educat-
ing patients and their caregivers may decrease the inci-
dence of ITB withdrawal syndrome. Oral baclofen
replacement may not be an effective method to treat or
prevent ITB withdrawal syndrome. Early recognition of
syndrome, high-dose benzodiazepines, prompt analysis
of the ITB pump with reinstitution of baclofen, and
proper intensive care management are mainstays for the
management of ITB withdrawal syndrome.
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